Liminatus Pharma, Inc.
LIMN
$0.18
$0.00-2.17%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 2.70M | 1.99M | 1.47M | 548.30K | 644.70K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 300.00 | 300.00 | 300.00 | 300.00 | -- |
| Total Operating Expenses | 2.70M | 1.99M | 1.83M | 1.62M | 3.33M |
| Operating Income | -2.70M | -1.99M | -1.83M | -1.62M | -3.33M |
| Income Before Tax | -9.88M | -1.94M | -718.20K | -1.79M | -3.55M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -9.88 | -1.94 | -0.72 | -1.79 | -3.55 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -9.88M | -1.94M | -718.20K | -1.79M | -3.55M |
| EBIT | -2.70M | -1.99M | -1.83M | -1.62M | -3.33M |
| EBITDA | -2.70M | -1.82M | -1.12M | -- | -- |
| EPS Basic | -0.36 | -0.08 | -0.04 | -0.10 | -0.20 |
| Normalized Basic EPS | -0.11 | -0.10 | -0.06 | -0.06 | -0.13 |
| EPS Diluted | -0.36 | -0.08 | -0.04 | -0.10 | -0.20 |
| Normalized Diluted EPS | -0.11 | -0.10 | -0.06 | -0.06 | -0.13 |
| Average Basic Shares Outstanding | 103.42M | 93.82M | 84.32M | 78.51M | 70.00M |
| Average Diluted Shares Outstanding | 103.42M | 93.82M | 84.32M | 78.51M | 70.00M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |